Neurotherapeutic applications of nanoparticles in Alzheimer's disease

Autor: Charles Ramassamy, Lé Dao, Sihem Doggui, Jasjeet K Sahni, Javed Ali, Sanjula Baboota
Přispěvatelé: Institut Armand Frappier (INRS-IAF), Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP), Department of Pharmaceutics, Faculty of Pharmacy-Jamia Hamdard, Faculté de Médecine, Université Laval [Québec] (ULaval), The financial support from NSERC (LD) and FQRNT (LD, CR) is gratefully acknowledged.
Rok vydání: 2011
Předmět:
Pathology
Pharmaceutical Science
Disease
MESH: Chelating Agents
Bioinformatics
MESH: Blood-Brain Barrier
Drug Delivery Systems
MESH: Phenols
MESH: Hormones
Degenerative disease
MESH: Animals
Chelating Agents
media_common
education.field_of_study
MESH: Vasoactive Intestinal Peptide
Blood-Brain Barrier
[SDV.TOX]Life Sciences [q-bio]/Toxicology
Drug delivery
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Alzheimer's disease
MESH: Cholinesterase Inhibitors
Vasoactive Intestinal Peptide
Drug
Amyloid
medicine.medical_specialty
media_common.quotation_subject
MESH: Drug Delivery Systems
Population
Phenols
Alzheimer Disease
medicine
Animals
Humans
education
Flavonoids
MESH: Amyloid
MESH: Humans
business.industry
Polyphenols
medicine.disease
Hormones
Targeted drug delivery
Nanoparticles
Cholinesterase Inhibitors
Nanocarriers
business
MESH: Flavonoids
MESH: Alzheimer Disease
MESH: Nanoparticles
MESH: Polyphenols
Zdroj: Journal of Controlled Release
Journal of Controlled Release, Elsevier, 2011, 152 (2), pp.208-31. ⟨10.1016/j.jconrel.2010.11.033⟩
ISSN: 0168-3659
DOI: 10.1016/j.jconrel.2010.11.033
Popis: International audience; A rapid increase in incidence of neurodegenerative disorders has been observed with the aging of the population. Alzheimer's disease (AD) is the most common neurodegenerative disorder among the elderly. It is characterized by memory dysfunction, loss of lexical access, spatial and temporal disorientation and impairment of judgement clinically. Unfortunately, clinical development of drugs for the symptomatic and disease-modifying treatment of AD has resulted in both promise and disappointment. Indeed, a large number of drugs with differing targets and mechanisms of action were investigated with only a few of them being clinically available. The targeted drug delivery to the central nervous system (CNS), for the diagnosis and treatment of neurodegenerative disorders such as AD, is restricted due to the limitations posed by the blood-brain barrier (BBB) as well as due to opsonization by plasma proteins in the systemic circulation and peripheral side-effects. Over the last decade, nanoparticle-mediated drug delivery represents one promising strategy to successfully increase the CNS penetration of several therapeutic moieties. Different nanocarriers are being investigated to treat and diagnose AD by delivering at a constant rate a host of therapeutics over times extending up to days, weeks or even months. This review provides a concise incursion on the current pharmacotherapies for AD besides reviewing and discussing the literature on the different drug molecules that have been successfully encapsulated in nanoparticles (NPs). Some of them have been shown to cross the BBB and have been tested either for diagnosis or treatment of AD. Finally, the route of NPs administration and the future prospects will be discussed.
Databáze: OpenAIRE
Externí odkaz: